480
Views
11
CrossRef citations to date
0
Altmetric
Safety of secukinumab on Psoriasis: evidences from real life experiences

Candida infections in psoriatic patients on anti-IL17 therapy: a case series

&
Pages 3-4 | Received 15 Feb 2018, Accepted 25 Sep 2018, Published online: 25 Dec 2018

References

  • Lønnberg A, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014;7:251–259.
  • Saunte D, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177:47–62.
  • Marinoni B, Ceribelli A, Massarotti M, et al. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights. 2014;5:9–19.
  • Picciani B, Michalski-Santos B, Carneiro S, et al. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. J Am Acad Dermatol. 2013;68:986–991.
  • Taheri Sarvtin M, Shokohi T, Hajheydari Z, et al. Evaluation of candida colonization and specific humoral responses against Candida albicans in patients with psoriasis. Int J Dermatol. 2014;53:e555–e560.
  • Zisova L, Valtchev V, Sotiriou E, et al. Onychomycosis in patients with psoriasis-a multicentre study. Mycoses. 2012;55:143–147.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.